Catalog No.
DHB91703
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG2-kappa
Clonality
Monoclonal
Applications
Research Grade Biosimilar
Target
Beta-nerve growth factor, NGFB, Beta-NGF, NGF
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P01138
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
4D4, AMG-403, JNJ-42160443, CAS: 902141-80-4
Clone ID
Fulranumab
Note
For research use only. Not suitable for clinical or therapeutic use.
Efficacy, safety, and tolerability of fulranumab, an anti-nerve growth factor antibody, in the treatment of patients with moderate to severe osteoarthritis pain., PMID:23748114
Anti-nerve growth factor in the treatment of low back pain and radiculopathy: a systematic review and a meta-analysis., PMID:24452657
Development of a method that eliminates false-positive results due to nerve growth factor interference in the assessment of fulranumab immunogenicity., PMID:24590506
Targeting nerve growth factor (NGF) for pain management: what does the future hold for NGF antagonists?, PMID:24691709
Fulranumab for treatment of diabetic peripheral neuropathic pain: A randomized controlled trial., PMID:25008392
Serious joint-related adverse events in randomized controlled trials of anti-nerve growth factor monoclonal antibodies., PMID:25527216
A systematic review of the efficacy and general safety of antibodies to NGF in the treatment of OA of the hip or knee., PMID:25527221
Antibodies to watch in 2016., PMID:26651519
Efficacy, Safety, and Tolerability of Fulranumab as an Adjunctive Therapy in Patients With Inadequately Controlled, Moderate-to-Severe Chronic Low Back Pain: A Randomized, Double-blind, Placebo-controlled, Dose-ranging, Dose-loading Phase II Study., PMID:27101815
Fulranumab in Patients With Pain Associated With Postherpetic Neuralgia and Postraumatic Neuropathy: Efficacy, Safety, and Tolerability Results From a Randomized, Double-blind, Placebo-controlled, Phase-2 Study., PMID:27153360
Efficacy and safety of fulranumab as monotherapy in patients with moderate to severe, chronic knee pain of primary osteoarthritis: a randomised, placebo- and active-controlled trial., PMID:27238963
Anti-nerve growth factor in pain management: current evidence., PMID:27354823
Long-Term Safety and Efficacy of Fulranumab in Patients With Moderate-to-Severe Osteoarthritis Pain: A Phase II Randomized, Double-Blind, Placebo-Controlled Extension Study., PMID:27748055
Fulranumab in patients with interstitial cystitis/bladder pain syndrome: observations from a randomized, double-blind, placebo-controlled study., PMID:28056917
Development of pain therapies targeting nerve growth factor signal transduction and the strategies used to resolve safety issues., PMID:29415946
Fulranumab as Adjunctive Therapy for Cancer-Related Pain: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study., PMID:30368018
Evaluation of the Toxicity and Neurological Effects of Fulranumab in Adult Cynomolgus Monkeys., PMID:30852923
Emerging therapies in clinical development and new contributions for neuropathic pain., PMID:31010688
Safety and efficacy of fulranumab in osteoarthritis of the hip and knee: results from four early terminated phase III randomized studies., PMID:31387410
Targeting nerve growth factor, a new option for treatment of osteoarthritis: a network meta-analysis of comparative efficacy and safety with traditional drugs., PMID:33293475
Different Drugs for the Treatment of Painful Diabetic Peripheral Neuropathy: A Meta-Analysis., PMID:34777192
Monoclonal Antibody Therapy for the Treatment of Interstitial Cystitis., PMID:35619987
Investigational Drugs for the Treatment of Postherpetic Neuralgia: Systematic Review of Randomized Controlled Trials., PMID:37629168
Standardized efficacy and safety evaluation of fulranumab for osteoarthritis., PMID:39998601
Targeting nerve growth factor, a new option for treatment of osteoarthritis: a network meta-analysis of comparative efficacy and safety with traditional drugs, PMID: 33293475
Targeting nerve growth factor (NGF) for pain management: what does the future hold for NGF antagonists?, PMID: 24691709
Serious joint-related adverse events in randomized controlled trials of anti-nerve growth factor monoclonal antibodies, PMID: 25527216
Safety and efficacy of fulranumab in osteoarthritis of the hip and knee: results from four early terminated phase III randomized studies, PMID: 31387410
Long-Term Safety and Efficacy of Fulranumab in Patients With Moderate-to-Severe Osteoarthritis Pain: A Phase II Randomized, Double-Blind, Placebo-Controlled Extension Study, PMID: 27748055
Fulranumab in Patients With Pain Associated With Postherpetic Neuralgia and Postraumatic Neuropathy: Efficacy, Safety, and Tolerability Results From a Randomized, Double-blind, Placebo-controlled, Phase-2 Study, PMID: 27153360
Fulranumab in patients with interstitial cystitis/bladder pain syndrome: observations from a randomized, double-blind, placebo-controlled study, PMID: 28056917
Fulranumab for treatment of diabetic peripheral neuropathic pain: A randomized controlled trial, PMID: 25008392
Fulranumab as Adjunctive Therapy for Cancer-Related Pain: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study, PMID: 30368018
Evaluation of the Toxicity and Neurological Effects of Fulranumab in Adult Cynomolgus Monkeys, PMID: 30852923
Emerging therapies in clinical development and new contributions for neuropathic pain, PMID: 31010688
Efficacy, safety, and tolerability of fulranumab, an anti-nerve growth factor antibody, in the treatment of patients with moderate to severe osteoarthritis pain, PMID: 23748114
Efficacy, Safety, and Tolerability of Fulranumab as an Adjunctive Therapy in Patients With Inadequately Controlled, Moderate-to-Severe Chronic Low Back Pain: A Randomized, Double-blind, Placebo-controlled, Dose-ranging, Dose-loading Phase II Study, PMID: 27101815
Efficacy and safety of fulranumab as monotherapy in patients with moderate to severe, chronic knee pain of primary osteoarthritis: a randomised, placebo- and active-controlled trial, PMID: 27238963
Development of pain therapies targeting nerve growth factor signal transduction and the strategies used to resolve safety issues, PMID: 29415946
Development of a method that eliminates false-positive results due to nerve growth factor interference in the assessment of fulranumab immunogenicity, PMID: 24590506
Anti-nerve growth factor in the treatment of low back pain and radiculopathy: a systematic review and a meta-analysis, PMID: 24452657
Anti-nerve growth factor in pain management: current evidence, PMID: 27354823
Antibodies to watch in 2016, PMID: 26651519
A systematic review of the efficacy and general safety of antibodies to NGF in the treatment of OA of the hip or knee, PMID: 25527221
For research use only. Not for human or drug use.
